Phase I/II clinical study of WT4869 peptide-based immunotherapy in patients with completely resected stage IA with vascular invasion, stage IB and stage II non-small cell lung cancer with WT1 antigen positive. - Phase I/II clinical study of WT4869 peptide-based immunotherapy in patients with completely resected stage IA with vascular invasion, stage IB/II NSCLC with WT1 antigen positive.

Osaka University Graduate School of Medicine, Department of Functional Diagnosis0 个研究点目标入组 237 人开始时间: 2013年2月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients with residual tumor after surgery. 2. Patients with active double cancer. 3. Patients requiring systemic-immunosuppressive agents or moderate or higher dose of steroid within 28 days before enrollment. 4. Patients had a blood transfusion or administered hematopoietic factor formulation within 14 days before enrollment. 5. Patients administered the other study drug or investigational product within 28 days before enrollment. 6. Patients with history of WT1 peptide administration. 7. Patients with HIV antibody, HBs antigen, HCV antibody positive. 8. Patients with MDS, MDS/MPD, MPD. 9. Patients with pulmonary fibrosis or interstitial pneumonitis. 10.Patients with severe complication. 11.Patients with history of allergy for oil formulation and severe drug hypersensitivity. 12.Pregnant or lactating women or women for childbearing potential, and men who want to get partner pregnant. 13.Patients with psychosis. 14.Inadequate physical condition, as diagnosed by the primary physician.

发起方

Osaka University Graduate School of Medicine, Department of Functional Diagnosis